The Bio-Identical Hormones Replacement Market Is Likely To Grow At A CAGR Of 5.1% Through 2032

Coloured Lenses Market

Bio-identical hormone replacement process involves plant-based estrogens that are used to resemble hormones produced by the human body. In recent years, bio-identical hormone replacement has noticed rising demand as there is an increase in hormone-related health issues. The hormonal issues rise with the declining levels of hormones with rising age. These changes are visible in weight gain, lower body energy, and lack of sleep.

Maintaining the hormonal balance in the body drives the growth of hormone replacement therapies. The rising lifestyle stress and increasing cancer cases globally are likely to have a stake in the demand for hormonal replacement treatment in the future. There is rising awareness about treating hormonal deficiencies, which is a key factor for growth in the market in recent years.

Hormonal replacement therapy is widely gaining acceptance in women patients as they are effective in treating menopause, unusual weight gain, vaginal dryness, and mood swings. The rising awareness among women regarding health issues has a positive impact on the growth of the bio-identical hormone replacement therapy market. With more women becoming financially stable, this market is expected to continue growing in the forecast duration.

For More Valuable Information on Regional Market Dynamics, Request a Report Sample –

Players Optimize the Efficiency of Bio-identical Hormones for Better Sales

The results of bio-identical hormone treatment are likely to differ from person to person depending on the body considerations and health history of a person. The consultation of a healthcare person essentially has a crucial role in spreading the right awareness about the possible impacts and benefits associated with bio-identical hormone treatment among people. Bio-identical hormone replacement therapy is suggested by experts over traditional hormone replacement treatments.

Risks Associated with Bio-identical Hormone Replacement Therapy that is likely to Affect Market Growth

There is considerable risk carried with these therapies, including side effects on the body and heart. There are incidences of heart conditions found in patients after hormone replacement, including stroke and attacks. As per the research of Cleveland Clinic, There is a risk of blood clots and gallbladder diseases associated with hormone therapies.

The compounded bio-identical hormones are associated with the risks as they are not approved by FDA and not suggested by health experts due to their long-term side effects. However, these side effects are more in the initial stages as the body is new to the inserted hormones, and with time body gets adjusted to the new levels of hormones.

High cost and potential side effects are major restraints faced by this market. The lower healthcare expenditure of poor and developing economies further hinders the penetration of the bio-identical hormone replacement therapy market. Rising demand for menopausal hormone therapy is likely to result in a supply shortage, increasing the struggle for players in the market.

Segment wise analysis

Oral insertion of hormones is preferred for ease of administration

Based on the way to administrate, the oral insertion of hormones has the largest market share in 2022. This is expected to grow in the forecast duration. Oral therapies are mostly preferred for the ease of administration associated with them. However, oral hormone replacement therapy has disadvantages, such as the need for daily dosing. These doses are relatively high compared with doses used parenterally.

There are variations in intestinal absorption and an increase in plasma triglyceride levels leading to alteration in hepatic proteins. Moreover, there is a concern about the elevation of triglyceride levels with oral estragon, an important risk factor for cardiovascular disease.

Parenteral administration is associated with a new matrix transdermal alcohol-free and causes lower skin reactions. This method does not affect the plasma profile, unlike the oral route. There is a reduced risk of cardiovascular diseases in parenteral ways owing to controlled trials.

Speak To Research Analyst For Detailed Insights:

 Strategies by Bio-Identical Hormones Replacement Therapy Market Player

The players in the global hormone replacement therapy market experience higher competition as the industry is driven by key companies that focus on gaining maximum share and applying market competencies. These players rely on collaborations, strategic partnerships, and acquisitions. Standards of services, and assistance before and post therapies are also decisive factors for industry players to maintain customer trust and edge in markets.

In October 2018, TherapeuticsMD received FDA approval for its TX-001HR: BIJUVA™ capsules for the treatment of moderate to severe vasomotor symptoms of menopause. According to the company, it is the first and only bio-identical hormone therapy approved by the FDA which uses a combination of estradiol and progesterone.

The Biostation has recently launched educational eBooks for uncovering root causes and solutions for making customers aware of their health. These guides are designed to give information and treatment solutions leading to customer trust.

Bio-identical Hormones Replacement Therapy Market: Segmentation

The global bio-identical hormones replacement therapy market has been segmented :

By Administration

  • Oral
  • Parenteral
  • Other

By Segment

  • Menopause
  • Growth hormone deficiency
  • Other

By Type

  • Estrogens
  • Progesterone
  • Testosterone
  • Others

By Product Type

  • Tablets and capsules
  • Creams and gels
  • Injectable
  • Patches and Implants
  • Others

By End User

  • Hospitals
  • Clinics
  • Research and academics
  • Others

By Region

  • North America
  • Latin America
  • Europe
  • Japan
  • APEJ
  • MEA

For in-depth competitive analysis, Buy Now –

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.


US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Visit Our Website: